EVALATION OF RELATIONSHIP BETWEEN MARKERS OF LIVER FUNCTION AND THE ONSET OF TYPE 2 DIABETES
Background and Objective: Type 2 diabetic individuals are highly prone to liver function test abnormalities than non-diabetic individuals. Increased activities of liver enzymes such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and ?- glutamyl transpeptidase (GGT) are indicators of hepatocellular injury. Increased activity of these markers is associated with insulin resistance , metabolic syndrome, and type 2 diabetes. Diabetes mellitus burden is one of the key concerns in developing countries like India. In this study, we evaluated the relationships between markers of liver function and the onset of type 2 diabetes.
Materials and Methods: This study was conducted after the approval from institutional ethical committee. Twenty five patients reporting to the OPD of K. S. Hegde Hospital diagnosed for type 2 diabetes between the age group of 40-50 years of both sex and 25 healthy age and sex matched individuals were included in the study. Under aseptic precautions blood samples were collected and centrifuged to get serum and was used for estimation. Data were expressed as the mean ± SD. Spearman's correlation coefficients were calculated to evaluate the relationship between serum glucose and liver function enzymes.
Result: The results of the present showed that the ALT, AST and GGT levels in Type 2 Diabetic patients was increased significantly (p<0.01) as compared to normal controls.
Conclusion: In this study, we found an association between the level of liver enzymes, ALT, AST and GGT in type 2 diabetes. Thus these liver enzyme levels can be used as a biomarker for the assessment of type 2 diabetes.
24 April 2020 (online)
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes , 2001:50:1844–1850.
- 2 Wannamethee SG, Shaper AG, Lennon L, Whincup PH: Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care, 2005; 28: 2913–2918.
- 3 Perry IJ, Wannamethee SG, Shaper AG: Prospective study of serumglutamyltransferase and risk of NIDDM. Diabetes Care, 1998; 21:732–737.
- 4 Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, (2004) Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 53: 2623–2632.
- 5 Nakanishi N, Suzuki K, Tatara K (2004) Serum gammaglutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 27: 1427–1432.
- 6 Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G,. (2009) Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and metaanalysis. Diabetes Care 32: 741–750.
- 7 Lewis GF, Carpentier A, Khosrow A, Giacca A: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23: 201-229,2002.
- 8 Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL: Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ab/ab mice. Mol Cell6 : 77-86,2000.
- 9 Neuschwander-TetriBA, Caldwell S: Nonalcoholic steatohepatitis: summary of AASLD single topic conference. Hepatology37 : 1202-1219,2003.
- 10 Grove J, Daly AK, Bassendine MF, Day CP: Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 26:143-146, 1997.
- 11 O'Brien RM, Granner DK: Regulation of gene expression by insulin. Biochem J 278: 609-619,1991.
- 12 . Wannamethee G, Ebrahim S , Shaper AG: Gamma - glutamyltransferase: determinants and associations with mortality from ischaemic heart disease and all causes. Am J Epidemiol 42:699-708, 1995.
- 13 Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Elevated alanine aminotransferase predicts new onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 53:2855–2860, 2004.
- 14 Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA: High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51:1889–1895, 2002.
- 15 Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM, Stern MP, Ferrannini E: Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City Diabetes Study. Diabetes Care 28:1757–1762, 2005.
- 16 Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM: Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54: 3140–3147, 2005.
- 17 Harsh Mohan: Textbook of Pathology, Sixth Edition: 2010 ISBN: 978-81-8448-702-2.